E3 ligase ligand-linker conjugates 37 are primarily used in targeted protein degradation strategies, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). These molecules play a critical role in recruiting E3 ubiquitin ligases to specific target proteins, marking them for degradation by the ubiquitin-proteasome system. This approach is valuable in drug discovery, especially for targeting undruggable proteins or those resistant to traditional inhibitors. It has potential applications in treating diseases like cancer, neurodegenerative disorders, and viral infections by selectively eliminating disease-causing proteins. The linker component ensures proper spatial orientation between the E3 ligase and the target protein, enhancing efficiency and specificity.